• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FCGR3B Gene Record

  • Summary
  • Interactions
  • Claims
  • FCGR3B 2215 Druggable Genome

    Alternate Names:

    2215
    FC FRAGMENT OF IGG RECEPTOR IIIB
    FCGR3B
    CD16
    CD16b
    FCG3
    FCGR3
    FCR-10
    FCRIII
    FCRIIIb
    610665
    3620
    ENSG00000162747
    OTTHUMG00000074099
    BE0000901
    O75015

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (0 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Snyder et al., 2005, Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer., Clin Colorectal Cancer
    Fujita et al., 2007, Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil., Intern. Med.
    Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.
    Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Hiatt A et al., 2014, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy., Proc Natl Acad Sci U S A
    Contasta et al., 1996, Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer., Cancer Biother. Radiopharm.
    Pellegrini et al., 1996, Immunological directives for biotherapy improvement in the treatment of colorectal cancer., Cancer Biother. Radiopharm.
    Bossowski et al., 2003, Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease., Pediatr. Res.
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
    Yeager et al., 2002, Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans., Anesth. Analg.
    Maes et al., 2007, Comparison of sample fixation and the use of LDS-751 or anti-CD45 for leukocyte identification in mouse whole blood for flow cytometry., J. Immunol. Methods
    Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
    Baj et al., 1992, T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment., Arch. Immunol. Ther. Exp. (Warsz.)
    Brett et al., 1996, Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H., Immunology
    Osterborg et al., 1997, Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)., Eur. J. Haematol.
    Nagler et al., 1997, Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells., Bone Marrow Transplant.
    Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
    Galandrini et al., 1993, Antibodies to CD44 trigger effector functions of human T cell clones., J. Immunol.
    Hoshino et al., 1991, Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders., Blood
    Martelletti et al., 1990, Defective expression of IL-2 receptors on peripheral blood lymphocytes from patients with cluster headache., Headache
    Hayakawa et al., 1991, The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone., J. Immunol.
    Lanier et al., 1985, Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen)., J. Exp. Med.
    Ozgocmen et al., 2007, Acute-phase response, clinical measures and disease activity in ankylosing spondylitis., Joint Bone Spine
    Hart et al., 2000, Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes., Cell Death Differ.
    Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
    Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
    Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
    Schomburg et al., 1992, Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma., Mol. Biother.
    Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.
    Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.
    Weber F et al., 2018, First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils., Pharm Res
    Takahashi et al., 2007, Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells., Scand. J. Immunol.
    Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
    Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
    Vendemiale et al., 1992, Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results., Arzneimittelforschung
    da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
    Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
    Seimetz D et al., 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy., Cancer Treat Rev
  • NATALIZUMAB   FCGR3B

    Interaction Score: 1.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29951887 17139284 17016423


    Sources:
    DrugBank

  • MUROMONAB-CD3   FCGR3B

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10851498 10851527


    Sources:
    DrugBank

  • ALEFACEPT   FCGR3B

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11970990


    Sources:
    DrugBank

  • LACTULOSE   FCGR3B

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1418064


    Sources:
    NCI

  • MAFOSFAMIDE   FCGR3B

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1515095


    Sources:
    NCI

  • ALEMTUZUMAB   FCGR3B

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8707338 9020367 9337053


    Sources:
    DrugBank

  • PALIVIZUMAB   FCGR3B

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423 24711420


    Sources:
    DrugBank

  • DACLIZUMAB   FCGR3B

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8097750 1835892 2335478 1900882 2415663


    Sources:
    DrugBank

  • PENICILLIN G POTASSIUM   FCGR3B

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17257217


    Sources:
    NCI

  • CATUMAXOMAB   FCGR3B

    Interaction Score: 0.49

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    20347527


    Sources:
    DrugBank

  • ETANERCEPT   FCGR3B

    Interaction Score: 0.47

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    17387033 10800083 15526004 19128982 15457442


    Sources:
    DrugBank

  • SARILUMAB   FCGR3B

    Interaction Score: 0.33

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • CHOLECALCIFEROL   FCGR3B

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9811059


    Sources:
    NCI

  • SODIUM CHLORIDE   FCGR3B

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17187818


    Sources:
    NCI

  • GELDANAMYCIN   FCGR3B

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662976


    Sources:
    NCI

  • ALDESLEUKIN   FCGR3B

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2528593 1827816


    Sources:
    NCI

  • METHIMAZOLE   FCGR3B

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12761360


    Sources:
    NCI

  • EPOETIN ALFA   FCGR3B

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1300984


    Sources:
    NCI

  • PUROMYCIN   FCGR3B

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8423352


    Sources:
    NCI

  • FENTANYL   FCGR3B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11772808


    Sources:
    NCI

  • PREDNISOLONE   FCGR3B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17329922


    Sources:
    NCI

  • THALIDOMIDE   FCGR3B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15457133


    Sources:
    NCI

  • HEPARIN   FCGR3B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18492254


    Sources:
    NCI

  • INDOMETHACIN   FCGR3B

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17329922


    Sources:
    NCI

  • CETUXIMAB   FCGR3B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16336752


    Sources:
    DrugBank

  • CYCLOSPORINE   FCGR3B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17852453


    Sources:
    NCI

  • PROGESTERONE   FCGR3B

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16635211


    Sources:
    NCI

  • DOXORUBICIN   FCGR3B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1830717


    Sources:
    NCI

  • METHOTREXATE   FCGR3B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9811059


    Sources:
    NCI

  • Ensembl: ENSG00000162747

    • Version: 101_38

    Alternate Names:
    FCGR3B Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • DrugBank: BE0000901

    • Version: 5.1.7

    Alternate Names:
    FCGR3B DrugBank Gene Name
    O75015 UniProt Accession
    2215 Entrez Gene Id

    Gene Info:

    Publications:
    Snyder et al., 2005, Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer., Clin Colorectal Cancer
    Ozgocmen et al., 2007, Acute-phase response, clinical measures and disease activity in ankylosing spondylitis., Joint Bone Spine
    Hart et al., 2000, Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes., Cell Death Differ.

  • NCI: FCGR3B

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.
    Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs

  • HingoraniCasas: ENSG00000162747

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000162747 Gene Symbol
    FCGR3B Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21